Welcome!

News Feed Item

Q3 Medical Devices Ltd: UKMMC Became The First Centre To Deploy Archimedes Biodegradable Biliary Stents In Asia

KUALA LUMPUR, Malaysia, March 24, 2014 /PRNewswire/ -- The Endoscopy Centre of UKM Medical Centre (UKMMC) is making history by successfully utilizing, first in Asia, a biodegradable stent on a 56 year old patient who presented acute cholangitis.

The novel biodegradable stent for biliary and pancreatic duct is a revolutionary new idea and it was made available by QualiMed Innovative Medizinprodukte GmbH, a Q3 Medical Devices Ltd, subsidiary, a well known innovative medical devices company from Germany.

The stent is made of well known polymers similar to the ones used in medical sutures. It remains in the biliary duct until the cholangitis is resolved, before it is slowly hydrolysed by the body. According to Dr. Hairol Othman, a consultant hepatobiliary and pancreas surgeon at UKMMC, a patient has to undergo another procedure to remove the stents, when using the conventional ones. 

The Archimedes device comes with three degradation times to accommodate the various disease states that require different indwelling times for treatment.  [Fast absorbing (weeks), medium absorbing (months), and a long last (closer to a half year)]  Unlike traditional plastic biliary stents that are used hundreds of thousands of times per year and have to be removed and/or exchanged routinely to relieve the Archimedes device can be used and implanted using the exact techniques applied with the existing technology with the added benefit of allowing the bile to flow on the outside of the devices as well as through the center helping to minimize the potential for post implant obstruction while eliminating the cost and risk associated with the removal procedures.  The elimination of removal procedures is expected to significantly reduce total procedure cost for the patients that are treated with the Archimedes device.  The device is for investigational purposes only and is not CE or FDA approved at this time.

Speaking after the successful surgery, Dr. Hairol said: "Archimedes biodegradable stents are a revolutionary new concept in the biliary and pancreatic duct drainage. They are easy to deploy and very convenient for the patients. They negate the need for a repeat ERCP, hence reducing patients' anxiety and inconvenience. Plus, they do incur only one cost compared to conventional stents."

The Endoscopy Centre of UKMMC has been chosen to participate in the multi-centre phase 1 clinical trial for the biodegradable stents in Asia.

Speaking on behalf of Q3 Medical and QualiMed Eric K Mangiardi, CEO of Q3 Medical, commented: "This is a significant milestone for the company as we continue to explore developments in the area of biodegradable implants, that will improve efficacy and eliminate cost for the patients and care givers that treat them. We are continuing our development in the areas of fully covered biodegradable esopahageal and balloon expandible biodegradable, covered and uncovered biodegradable biliary and peripheral vascular devices that will further the advancement and treatment options for patients and doctors globally." 

About Q3 Medical Devices Limited

Q3 Medical Devices Limited is an Irish based holding company with multiple operations in Germany and strong partnerships throughout Asia through its growing investor base, including China Pioneer Pharma Holdings Limited listed on the Hong Kong Exchange (1345). The holding and its companies are focused on the development, manufacturing and distribution of minimally invasive devices for the treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

Q3 Medical Devices Limited was formed by a global group of entrepreneurs, manufactures, distributors, industry doctors and investors, focused on the development and acquisition of medical device businesses with annual revenues between 1-10 Million. The acquisitions are targeted in areas that expand the groups manufacturing base and capabilities,  resulting in the growth of its distribution channels and accelerating its products offering, focusing on the minimally invasive treatment of patients with cardiology, peripheral vascular and non-vascular diseases.

About QualiMed

QualiMed, a wholly owned subsidiary of Q3 Medical, was founded in 1997 in Winsen, Germany near Hamburg, where it develops, manufactures and sells implantable medical devices in the Cardiology, Peripheral Vascular, and Non Vascular areas. The innovations are focused in the areas of Biodegradable Products, Drug Device Combination Technologies, Catheter and Mechanical implant areas. Originally founded as an OEM, the company's products are now sold in over 50 countries worldwide through its OEM, Private Label, and Own Brand Networks. The company and its development partners have obtained CE and FDA approvals for more than 70 different products including 3 different drug eluting stents.

Forward Looking Statements

This announcement includes "forward-looking statements" which incorporates all statements other than statements of historical facts, including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Group's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group´s present and future business strategies and the environment in which the Group will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to QualiMed's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements are valid at the date of this announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

For more enquiries and/or photos of event, please contact

Q3 Medical Devices Ltd
Investor Relations
Tel: +353867827296
http://www.q3medical.com

QualiMed Innovative Medizinprodukte GmbH
Investor Relations
Tel: +49(0)417165780 (main office)
http://www.qualimed.de

UKM Medical Centre (UKMMC), Cheras
Ms. Normahani Md. Ramdani
Public Relations Officer
(Tel)        03-91455053/6313
(H/P)       019-3220884
(Fax)       03-91456640
(Email)    mahani.ramdani@ppukm.ukm.edu.my
ALIZA MANSOR
Head
Department of Public Relations
UKM Medical Centre

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
Column Technologies exhibited at SYS-CON's @DevOpsSummit at Cloud Expo, which took place at the Javits Center in New York City, NY, in June 2016. Established in 1998, Column Technologies is a global technology solutions provider with over 400 employees, headquartered in the United States with offices in Canada, India, and the United Kingdom. Column Technologies provides “Best of Breed” technology solutions that automate the key DevOps principals and help our customers meet today’s DevOps and Dig...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.